Argos Therapeutics Provides Update on Clinical Research for

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Argos Therapeutics Provides Update on Clinical Research for Investigational Fully Personalized Immunotherapy for the Treatment of HIV

Findings from Phase 2b trial support clinical development of AGS-004 in adult eradication and pediatric studies.

Company to host conference call and webcast today at 8:30 a.m. ET.

DURHAM, N.C., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq: ARGS ) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on the Arcelis® technology platform, today provided an update on its clinical research program for AGS-004, the company's investigational fully personalized immunotherapy for the treatment of HIV. The company announced top-line results of its double-blind, placebo-controlled Phase 2b clinical trial of AGS-004 in patients chronically infected with HIV-1. The primary endpoint of the trial, which required a 1.1 Log lower median viral load (VL) after 12 weeks of interruption of antiretroviral therapy (ATI) in the treatment group versus the placebo group, was not achieved.

Importantly, however, data from the trial provided evidence of the ability of AGS-004 to induce memory T-cell responses which may have directly impacted the latent viral reservoir. Of the patients who received AGS-004 and completed ATI, approximately 70 percent had positive antiviral memory T-cell responses prior to ATI versus zero percent of placebo patients. Also, within the AGS-004 treatment group, those patients that had antiviral memory T-cell responses had significantly fewer CD4+ T-cells with integrated HIV DNA when compared to non-responders. These findings relate directly to the utilization of AGS-004 in an ongoing adult eradication study and a planned pediatric study, where one of the key objectives is to decrease the latent HIV reservoir. The ongoing adult eradication study is expected to enter stage two in the coming months, and the pediatric study is planned to initiate this year.

In the Phase 2b trial, 54 patients received four doses of AGS-004 or placebo every four weeks while on standard antiretroviral therapy (ART), and then began a 12-week ATI, during which dosing continued every four weeks. In total, 36 participants completed ATI, 23 of whom received AGS-004. The trial was fully funded by NIAID, NIH (No. NO1-A1-60019).

"By demonstrating that AGS-004 induced memory T-cell responses in a majority of patients and that those immune responders had fewer CD4+ T-cells with integrated HIV DNA, these data suggest that induced anti-viral memory T-cell responses may contribute to lower persistent viral reservoirs," said Dr. Charles Nicolette, chief scientific officer and vice president of R&D of Argos. "These data support our plans to continue testing AGS-004 in the studies aimed at decreasing or eliminating the latent HIV reservoir. In addition, based on these data we believe that more frequent dosing of AGS-004 during ART may provide further benefit, but also highlight the need to better understand the mechanisms of immune evasion employed by the HIV virus in the absence of ART."

"The results of the AGS-004 Phase 2b trial allow us to now ask if combining AGS-004 treatment with HDAC inhibitors, part of a new class of latent reservoir mobilizers, will lead to the elimination of HIV-infected cells," stated Dr. David Margolis of the University of North Carolina, principal investigator of the AGS-004 Phase 2a adult eradication study. "We look forward to initiating stage two of the adult eradication study where patients on ART will receive the HDAC inhibitor vorinostat in addition to AGS-004."

Conference Call and Webcast Information

Argos executive management will host a conference call beginning at 8:30 a.m. Eastern Time today to discuss the AGS-004 Phase 2b results and to answer questions. To participate by telephone, please dial (855) 433-0930 (Domestic) or (484) 756-4271 (International). The conference ID number is 63839906. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.argostherapeutics.com . The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About the Arcelis® Technology Platform

Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers and infectious diseases and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a second Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial in combination with a latency reversing drug for HIV eradication in adult patients. For more information about Argos Therapeutics, visit www.argostherapeutics.com .

Forward Looking Statements

Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if product candidates obtains approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos' Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 which is on file with the SEC. In addition, the forward-looking statements included in this press release represent the Argos' views as of January 9, 2015. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to January 9, 2015.

Media contact: Adam Daley Berry & Company Public Relations 212-253-8881 Investor contact: Nancy Yu Burns McClellan 212-213-0006

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 201

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
PepsiCo Nears Deforestation-Free Sourcing Milestone by 2025

Updated Category News Views 129

PepsiCo's Aim for a Greener Supply Chain Well, look who's climbing the environmental ladder—PepsiCo. They’ve apparently hit 94% deforestation-free sourcing for those high-stakes commodities their empire relies on. Maybe it's a wake-up call for the rest of 'em still smogging about. The endgame? Full-fledged deforestation-free sourcing by 2030. That’s no walk in the...

Continue Reading
Priceline's Cyber Week: A Pocket-Friendly Travel Bonanza

Updated Category News Views 146

Unpacking Priceline's Cyber Week Bonanza Alright, folks, grab your booking hats because Priceline is back with its annual Cyber Week extravaganza, aiming to give travelers a shot in the arm of savings just when inflation has everyone pinching pennies. From November 16 through December 2, Priceline rolls out the red carpet for vacation planners, offering eye-popping...

Continue Reading
New York Reclaims Bagel Crown at 2026 BagelFest

Updated Category News Views 139

A Bagel Victory at Citi Field Holy schmear! New Yorker's are grinning wide like a bagel with a double helping of cream cheese—Ess-a-Bagel from Manhattan snagged the top honors at the heavily contested 2026 New York BagelFest. Back in its rightful hands, the Bagel Crown stays in the Empire State, and it's a victory for tradition and taste. Celebrating 50 years in the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 103

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Exploring Why Dead Outlets Stay Dead: Expert Insights

Updated Category News Views 66

The Mystery of Non-Responsive Outlets Ever found an electrical outlet refusing to cooperate when you need it most? Well, I know the frustration all too well. You'd think if the breaker ain't blown, the outlet should work like a charm. But dive into the guts of the story, and you find a series of surprises waiting to trip us up. Common Culprits: Tripped GFCIs and Loose...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 35

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
MacKenzie-Childs Grinds Into Spotlight with Oprah's Nod

Updated Category News Views 50

Oprah's Golden Touch: 30 Years Strong Every year, there are a few select spots that brands covet like a hawk on a rabbit hunt. Getting on Oprah’s 'Favorite Things' list is surely one of them. Just like that, the MacKenzie-Childs Electric Salt and Pepper Grinder Set has muscled its way into the 2026 selection. Spare me the bells and whistles; this is like hitting the...

Continue Reading

Top 5 Most Recently Viewed Articles

Citi Raises Price Target for Blackstone Amid Encouraging Outlook

Updated Category News Views 131

Citi's Updated Outlook on Blackstone Recently, Citi revisited its financial forecast for The Blackstone Group (NYSE: BX), adjusting the price target upward from $157.00 to $170.00 while maintaining a Neutral stance on the stock. This update follows the company's impressive third-quarter performance, which saw Blackstone's stock rise by 6.3% post-earnings announcement....

Continue Reading
JAB's Strategic Acquisition of Mondelez Shares in JDE Peet's

Updated Category News Views 92

JAB's Significant Move in the Coffee Industry In a strategic and noteworthy development, JAB has made headlines by agreeing to acquire a substantial share package from Mondelez, focusing on Dutch coffee giant JDE Peet's. This major transaction amounts to approximately €2.2 billion, or about $2.4 billion. JAB intends to purchase 86 million shares at a price of €25.10...

Continue Reading
Urgent Update for DXC Technology Company Investors

Updated Category News Views 272

DXC Technology Company (NYSE: DXC) found itself in hot water back in 2024 when shareholders raised hell over alleged falsehoods that inflated stock prices. The Rosen Law Firm rolled out a class action lawsuit aimed at those who bought shares during what they dubbed the Class Period—a time rife with questionable operational claims from DXC's brass. Allegations Surface:...

Continue Reading
Investigation Launched: National Grid Faces Legal Scrutiny

Updated Category News Views 283

Bragar Eagel & Squire, P.C. Initiates Investigation Bragar Eagel & Squire, P.C., a well-regarded law firm known for advocating for investors, has begun an investigation surrounding concerns related to National Grid plc (NYSE: NGG). This inquiry primarily aims to assist stockholders who may have experienced losses while owning shares of National Grid. The firm invites...

Continue Reading
Oil & Gas Sector Trends: Path to 8.79 Trillion Growth

Updated Category News Views 223

Oil & Gas Market Growth and Projections The global oil and gas market has positioned itself for remarkable expansion. With estimates currently valuing the market at approximately USD 6.10 trillion, projections suggest it could soar to around USD 8.79 trillion by 2034. This growth translates to a compound annual growth rate (CAGR) of 3.72% between 2025 and 2034. Notably,...

Continue Reading